scholarly journals The Minor Product [Ph3Sb(Cl)O]3C• PhH in the Ligand Redistribution Reactions of Pentavalent Antimony Aryl Derivatives

2019 ◽  
Vol 11 (2) ◽  
pp. 58-65
Author(s):  
A. Efremov ◽  
1992 ◽  
Vol 30 (4) ◽  
pp. 613-623 ◽  
Author(s):  
V. Belot ◽  
R. J. P. Corriu ◽  
D. Leclercq ◽  
P. H. Mutin ◽  
A. Vioux

2009 ◽  
Vol 87 (8) ◽  
pp. 1163-1172 ◽  
Author(s):  
Osamah Alhomaidan ◽  
Gregory C. Welch ◽  
Guangcai Bai ◽  
Douglas W. Stephan

A series of phosphinimide complexes of Hf are prepared and characterized. Reaction of the phosphinimine t-Bu3PNH with Hf(NEt2)4 gave (t-Bu3PN)Hf(NEt2)3 (1) but this species was not readily converted to the corresponding HfCl3-derivative. The reaction of 2 equiv. of t-Bu3PNH with Hf(NEt2)4, however, gave (t-Bu3PN)2Hf(NEt2)2 (2), which was readily converted to (t-Bu3PN)2HfCl2 (3) and (t-Bu3PN)2HfMe2 (4). Employing t-Bu3PNLi and HfCl4 afforded (t-Bu3PN)3HfCl (5) while reaction with CpHfCl3 gave rise to ligand redistribution reactions affording (t-Bu3PN)2HfCl2 and Cp2HfCl2. However, Cp(t-Bu3PN)2HfCl (7) was prepared by treating (t-Bu3PN)2HfCl2 with CpNa. The related species of Cp2(t-Bu3PN)HfCl (8) was synthesized by the reaction of Cp2HfCl2 and t-Bu3PNLi. Ligand redistribution was avoided in the reaction of Cp*HfCl3 as Cp*(t-Bu3PN)HfCl2 (9) and Cp*(i-Pr3PN)HfCl2 (10) were readily obtained and derivatized as Cp*(t-Bu3PN)Hf(NMe2)2 (11) and Cp*(t-Bu3PN)HfMe2 (12), respectively. Similarly, ((Me3Si)2C5H3)(t-Bu3PN)HfCl2 (13) was converted to ((Me3Si)2C5H3)(t-Bu3PN)HfMe2 (14). Reactions with Lewis acid activators were used to prepare Cp*(t-Bu3PN)HfMe(THF)MeB(C6F5)3 (15), (Cp*(t-Bu3PN)HfMe)(B(C6F5)4) (16), and (t-Bu3PN)2Hf(H2B(C6F5)2)2 (17). Preliminary testing of 3, 9, and 13 in ethylene polymerization is reported. Compounds 3, 4, 7, 9, and 17 are characterized crystallographically.


2018 ◽  
Vol 12 (04) ◽  
pp. 279-283
Author(s):  
Julie Rambaldi ◽  
Andrea Barbarossa ◽  
Eva Morbidelli ◽  
Anna Zaghini

Introduction: Pentavalent antimony is the first choice drug for leishmaniasis in dog. Leishmaniasis has a complex pathogenesis and it manifests various clinical signs, some of which are often similar to those associated with the toxicity induced by antimonial treatment. Among the reasons for this toxicity, also a general problem of drug’s quality has been reported. Methodology: The general and local tolerability of two commercially available meglumine antimoniate based veterinary products was evaluated in 12 healthy dogs, 6 receiving Antimania (Fatro, Italy) and 6 receiving Glucantime (Merial, Spain), following repeated subcutaneous administrations of therapeutic doses for 14 days. Results: Individual and mean values of haematological and biochemical parameters in both groups remained in the physiological range, with no considerable differences within the two groups. The general tolerability of the drugs was also supported by clinical observations and physical examination of the dogs throughout the whole study period. Only slight local reactions at the injection sites, that spontaneously disappeared, were observed for both products starting from 12-84 hours after the administration. The pharmacokinetic parameters indicated no antimony accumulation. Conclusions: These results suggest that meglumine antimoniate administered at the recommended dosage regimen is well tolerated by healthy dogs, and that there is no significant difference between the two tested products.


Author(s):  
V. A. Chernoplekova ◽  
N. N. Zemlyanskii ◽  
N. D. Kolosova ◽  
K. A. Kocheshkov

Infection ◽  
1993 ◽  
Vol 21 (6) ◽  
pp. 362-366 ◽  
Author(s):  
J. van Lunzen ◽  
J. Schmitz ◽  
J. Brazoska ◽  
Sabine Flessenkämper ◽  
M. Dietrich ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document